DSCO Key Stats
- 4 Stocks Under $10 Making Big Moves The Street Nov 27
- Discovery Labs (DSCO) Execs to Present at Piper Jaffray Health Care Conference Street Insider Nov 21
- Discovery Labs to Present at the 25th Annual Piper Jaffray Health Care Conference PR Newswire Nov 21
- DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Other Events Nov 14
- Discovery Laboratories Management Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 13
- DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Fina Nov 13
- Discovery Laboratories, Inc. (DSCO) Posts Q3 GAAP Loss of 22c/Share Street Insider Nov 12
- Discovery Labs Reports Third Quarter 2013 Financial Results PR Newswire Nov 12
- DISCOVERY LABORATORIES INC /DE/ Files SEC form 10-Q, Quarterly Report Nov 12
- Discovery Labs receives FDA clearance of IND for AEROSURF Phase 2 program Nov 12
DSCO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Discovery Laboratories is up 1.34% over the last year vs S&P 500 Total Return up 30.43%, Actelion up 63.63%, and Alcobra up N/A.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for DSCO
Pro Strategies Featuring DSCO
Did Discovery Laboratories make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Discovery Laboratories, Inc. is engaged in the development of Surfactant Replacement Therapies (SRT) to treat respiratory disorders and diseases for which there frequently are few or no approved therapies.